Hemophilia - Pipeline Assessment and Market Forecasts to 2017

23 Jul 2010 • by Natalie Aster

GlobalData, the industry analysis specialist, has released its new report, “Hemophilia - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global hemophilia therapeutics market was valued at $6.5 billion in 2009. It is expected to increase at a Compound Annual Growth Rate (CAGR) of 5.8% from $6.5 billion in 2009 to $10.4 billion by 2017. This slow growth of 5.8% is primarily attributed to a low diagnosis rate and the high cost of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX, a clotting factor from Pfizer Inc.

The Hemophilia Therapeutics Market is forecast to Show Slow Growth to 2017

GlobalData’s analysis suggests that the global hemophilia therapeutics market was valued at $6.5 billion in 2009. It is expected to increase at a Compound Annual Growth Rate (CAGR) of 5.8% from $6.5 billion in 2009 to $10.4 billion by 2017. This slow growth of 5.8% is primarily attributed to a low diagnosis rate and the high cost of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX, a clotting factor from Pfizer Inc.

Current Treatment Options Moderately Meet the Market Demand

GlobalData suggests that the hemophilia therapeutics market has moderate unmet need in terms of both safety and efficacy. The majority of the drugs available in the market belong to the ’recombinant coagulation factors’ drug class. NovoSeven, Xyntha and Kogenate FS are the main drugs available to treat hemophilia. Kogenate FS has been proved highly efficacious while NovoSeven has shown the fewer side effects. Kogenate FS is the only FDA-approved drug which increases clotting factor VIII.

Poor Diagnosis Rate of the Disease is a Major Barrier for the Hemophilia Therapeutics Market

The incidence of hemophilia is underestimated by the patients. Indeed, patients may be seen by several specialists and undergo dangerous investigations and interventions before the correct diagnosis is made. Most of the old patients with acquired hemophilia are associated with autoimmune diseases or cancer. Apart from misdiagnoses, acquired hemophilia may be under-diagnosed as many cases of clinically silent low titer inhibitors may be unrecognized unless patients undergo surgery or trauma. Therefore the low diagnosis rate is major barrier in the hemophilia therapeutics market.

Strong Pipeline Candidates are expected to Intensify Future Competition

The hemophilia therapeutics developmental pipeline is strong with about 31 molecules in various phases of clinical development. Most of the molecules in clinical development are first-in-class or me-too molecules. There are five molecules in Phase III including one first-in-class molecule. There is one first-in-class molecule in Phase I. There are 14 me-too molecules over all the phases of clinical development. There are eight first-in-class molecules which are in the discovery and preclinical phase. These molecules include classes such as recombinant coagulation factor, thrombin generation, gene therapy, stem cell therapy and plasma-derived coagulation factor molecules.

About GlobalData

GlobalData is an industry analysis specialist company providing business information products and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.